On January 6, 2023, Outlook Therapeutics, Inc. closed the transaction. The transaction included participation from one investor.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.98 USD | -2.60% |
|
+17.74% | +13.71% |
08/07 | Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug | MT |
01/07 | Outlook Therapeutics, Inc.(NasdaqCM:OTLK) added to Russell Small Cap Comp Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.71% | 22Cr | |
+21.87% | 4.8TCr | |
+0.78% | 4.24TCr | |
+43.96% | 4.15TCr | |
+26.26% | 3.16TCr | |
+20.87% | 2.86TCr | |
-4.47% | 2.8TCr | |
+52.11% | 1.46TCr | |
+45.42% | 1.41TCr | |
+2.64% | 1.26TCr |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Outlook Therapeutics, Inc. announced that it has received $30.02 million in funding from Streeterville Capital, LLC